The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Ishares Nasdaq Biotechnology

Nasdaq: IBB
Last

(U.S.) $373.58

Today's change0.00 0.00%
Updated July 27 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Ishares Nasdaq Biotechnology

Nasdaq: IBB
Last

(U.S.) $373.58

Today's change0.00 0.00%
Updated July 27 4:00 PM -4GMT. Delayed by at least 15 minutes.

Ishares Nasdaq Biotechnology closed at (U.S.)$373.58.

Shares have lost 6.14% over the last five days, but have gained 23.15% over the last year to date. This security has outperformed the S&P 500 by 42.53% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $373.58
  • High--
  • Low--
  • Bid / Ask(U.S.) $366.00 / (U.S.) $385.00
  • YTD % change+23.15%
  • Volume0
  • Average volume (10-day)1,967,816
  • Average volume (1-month)1,748,573
  • Average volume (3-month)1,739,673
  • 52-week range(U.S.) $247.35 to (U.S.) $400.79
  • Beta0.84
  • Trailing P/E4.11×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $0.11
  • Dividend yield0.03%
  • Trailing EPS(U.S.) $90.83
Updated July 27 4:00 PM -4GMT. Delayed by at least 15 minutes.
S&P TSX1.30%Sector:FinancialsIndustry:Investment Trusts
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q2/2015Q4/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Sep 30, 201409/30/2014Mar 31, 201403/31/2014Sep 30, 201309/30/2013
Revenue92198
Total other revenue--------
Total revenue92198
Gross profit--------
Total cost of revenue--------
Total operating expense1612118
Selling / general / administrative1612118
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-79-20
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax1,572718446878
Income after tax1,572718446878
Income tax, total0000
Net income1,572718446878
Total adjustments to net income--------
Net income before extra. items1,572718446878
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1,572718446878
Inc. avail. to common incl. extra. items1,572718446878
Diluted net income1,572718446878
Dilution adjustment----0--
Diluted weighted average shares29202319
Diluted EPS excluding extraordinary itemsvalue per share54.7736.0619.0345.62
Dividends per sharevalue per share0.000.450.000.07
Diluted normalized EPSvalue per share54.7736.0619.0345.62